Valitor
Berkeley, US · Founded 2018 · Delaware corporation · 5 known investors
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration. The company leverages its interchangeable platform to engineer medicines with extended therapeutic durability and improved potency for vision-threatening conditions.
Founders & leadership
Board
Investors · 5
Reported raises · per SEC filings
Form D private placements$10.2M disclosed across 2 rounds · 2018–2021
▶$8.4MraisedJan 2022 · 8 investors · OtherRule 506(b)
- Walter MoosDirector
- Anthony AiudiDirector
- Kevin E. HealyDirector
- Gail MaderisDirector
- Manish KothariDirector
- Wesley M. JacksonExecutive Officer, Director
- Offering amount
- $32.7M
- Amount sold
- $8.4M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$1.7MraisedSep 2018 · 6 investors · OtherRule 506(b)
- Carole H BellisExecutive Officer
- Drew LanzaDirector
- Kevin E HealyDirector
- Walter MoosDirector
- Jackson M WesleyExecutive Officer, Director
- Offering amount
- $2.8M
- Amount sold
- $1.7M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapCompanies competing with Valitor for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 9 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $298.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $318.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $284.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $310.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $311.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Valitor do?
- Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration. The company leverages its interchangeable platform to engineer medicines with extended therapeutic durability and improved potency for vision-threatening conditions.
- Who are Valitor's investors?
- Valitor's investors include Angel Physicians Fund, Berkeley Catalyst, ExSight Ventures, First Spark Ventures, Llc, Pandect Bioventures.
- How much funding has Valitor raised?
- Valitor has disclosed $10.2M raised across 2 rounds.
- Where is Valitor headquartered?
- Valitor is headquartered in Berkeley, US.